Menu
Search
|

Menu

Close
X

Prometic Life Sciences Inc PLI.TO (Toronto Stock Exchange)

1.49 CAD
+0.03 (+2.05%)
As of Feb 23
chart
Previous Close 1.46
Open 1.47
Volume 493,846
3m Avg Volume 908,467
Today’s High 1.49
Today’s Low 1.44
52 Week High 2.52
52 Week Low 1.12
Shares Outstanding (mil) 711.93
Market Capitalization (mil) 1,060.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.17 Mean rating from 12 analysts

KEY STATS

Revenue (mm, CAD)
FY17
33
FY16
16
FY15
25
EPS (CAD)
FY17
-0.107
FY16
-0.167
FY15
-0.090
*Note: Units in Millions of Canadian Dollars
**Note: Units in Canadian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
28.96
8.35
Price to Book (MRQ)
vs sector
7.04
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
44.83
15.84
LT Debt to Equity (MRQ)
vs sector
42.17
12.39
Return on Investment (TTM)
vs sector
-55.10
13.63
Return on Equity (TTM)
vs sector
-80.53
15.39

EXECUTIVE LEADERSHIP

Simon Best
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Pierre Laurin
President, Chief Executive Officer, Non-Independent Director, Since 2011
Salary: $625,585.00
Bonus: $424,125.00
Bruce Pritchard
Interim Chief Financial Officer, Chief Operating Officer, Since 2017
Salary: $531,226.00
Bonus: $284,272.00
John Moran
Chief Medical Officer, Director, Since 2014
Salary: $447,041.00
Bonus: $150,440.00
Patrick Sartore
Chief Legal Officer and Corporate Secretary, Since 2015
Salary: $373,462.00
Bonus: $177,200.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

440 Armand-Frappier Blvd Suite 3
LAVAL   QC   H7V 4B4

Phone: +1450.7810115

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

SPONSORED STORIES